NEW YORK, June 24-Genzyme Molecular Oncology and Silico Insights will jointly market the SAGE gene expression system and the I-Sight Discovery informatics platform, the two companies said today.
The companies did not disclose financial details of the agreement.
The two companies are using the two systems together to identify tags and genes that may be useful in breast cancer diagnosis and treatment. Silico Insights is also analyzing GMO's tumor endothelial markers for potential applications in anti-angiogenesis.
Genzyme Molecular Oncology is a division of Genzyme. Its "serial analysis of gene expression" platform is licensed from Johns Hopkins University.
Silico Insights is an informatics company based in Woburn, Mass.